[Congressional Record (Bound Edition), Volume 150 (2004), Part 8]
[Senate]
[Page 11032]
[From the U.S. Government Publishing Office, www.gpo.gov]




                      TRIBUTE TO DR. BART BARLOGIE

 Mrs. LINCOLN. Mr. President, I rise today with my colleague 
Senator Mark Pryor to honor Dr. Bart Barlogie, professor of medicine 
and pathology at the University of Arkansas for Medical Sciences, UAMS, 
the Arkansas Cancer Research Center, ACRC, and director of the Myeloma 
Institute for Research and Therapy, MIRT.
  For his lifelong work to find innovative treatments for myeloma 
cancer, Dr. Barlogie received the International Myeloma Foundation's 
Second Robert A. Kyle Lifetime Achievement Award on May 8, 2004, in 
Little Rock, AR.
  Throughout his career, Dr. Barlogie has been recognized as one of the 
most innovative, creative, and knowledgeable minds in the field of 
myeloma clinical research and treatment. His leadership has made 
Arkansas home to the foremost center for myeloma research and treatment 
in the world.
  Innovations pioneered under Dr. Barlogie's leadership include the 
accepted use of bone marrow and peripheral blood stem cell transplants 
that have resulted in better clinical outcomes for myeloma patients. In 
fact, the MIRT has performed more than 4,400 bone marrow transplants, 
far more than anywhere else.
  Dr. Barlogie's work will thalidomide as a treatment for myeloma has 
dramatically changed how patients are treated. His use of anti-
angiogenesis as a cancer treatment is now widely accepted and used in 
not only myeloma but many other forms of cancer.
  Over the last 10 years, Dr. Barlogie's work has led to the widespread 
use and acceptance of magnetic resonance imaging, MRI, and positron 
emission tomography, PET, scans for myeloma patients. His work is also 
on the forefront of the movement toward effective molecularly targeted 
therapies and treatments. These techniques continue to improve the 
means by which physicians can combat cancer.
  Dr. Barlogie is totally devoted to his patients. He is continually 
driven to find better therapies, prolonged remission rates, a better 
quality of life, and, ultimately, a cure to one of the most challenging 
and misunderstood of all cancers.
  I am proud to honor Dr. Barlogie today, and I am happy that he, his 
wife Kathleen, and their three children, Britta, Eva, and Bart, have 
made their home in Little Rock, AR. They have made significant 
contributions to our State and community.
  I know all Arkansas join me in thanking Dr. Barlogie for making 
Arkansas the center of his professional and personal life. His 
achievements have helped make our stellar medical institutions, the 
University of Arkansas for Medical Sciences, the Arkansas Cancer 
Research Center, and the Myeloma Institute for Research and Therapy, 
gain worldwide prominence in the fight against cancer.
 Mr. PRYOR. Mr. President, I rise today with my colleague, 
Senator Blanche Lincoln, to honor Dr. Bart Barlogie.
  I am pleased to have this opportunity to publicly commend Dr. 
Barlogie for his unyielding dedication and stalwart leadership in the 
field of oncology research and treatment. His hard work has led to the 
development of innovative and comprehensive approaches to treatment of 
patients with multiple myeloma, which has translated better therapies, 
prolonged remission rates for cancer survivors and improved the quality 
of life for many of his patients. Moreover, his commitment may 
ultimately lead to a cure for the most challenging and misunderstood of 
all cancers.
  On May 8, 2004, Dr. Barlogie was awarded the International Myeloma 
Foundation's Second Robert A. Kyle Lifetime Achievement Award. This 
award, which is being given for only the second time, recognizes the 
significant and revolutionary work of his professional career. This 
award follows an already long and distinguished line of 
accomplishments.
  Arkansas was well on its way to becoming the center for myeloma 
clinical research and treatment when Dr. Barlogie accepted the position 
of director of hematology/oncology, and director of research at the 
Arkansas Cancer Research Center, (ACRC), at the University of Arkansas 
for Medical Sciences, (UAMS, and founding director of the Myeloma and 
Transplantation Research Center, MTRC, within the ACRC. His research 
team has developed innovative and comprehensive approaches to the 
treatment of patients with multiple myeloma. Because of his leadership 
role in the area of myeloma research and treatment, he was named the 
first director of a newly established Myeloma Institute for Research 
and Therapy.
  During Dr. Barlogie's 15-year tenure at UAMS, more myeloma patients 
have been treated in Arkansas than anywhere else in the world. Yet, 
despite his gains in this area, myeloma continues to affect thousands. 
This year, approximately 15,000 Americans will be diagnosed with 
myeloma. Looking to the future, Dr. Barlogie envisions a satellite-
based intensive training program which will reach physicians worldwide 
so that many of these patients treated at the institute will have 
access to specialized medical care upon returning to their home States 
or countries.
  Of paramount importance to Dr. Barlogie are his wife Kathleen and 
their three children, Britta, Eva, and Bart. He loves them dearly and 
credits their support for his success. They have made their home in 
Little Rock, AR, and have added a number of their own contributions to 
our community and State.
  We thank Dr. Barlogie for making Arkansas the center of his 
professional and personal life. His past and future achievements have 
truly helped make the University of Arkansas for Medical Sciences, the 
Arkansas Cancer Research Center, and the Myeloma Institute for Research 
and Therapy very respectable among the premier health care institutions 
in the State. More importantly, through his work, Dr. Barlogie has had 
concrete and positive impacts on the everyday lives of thousands of his 
patients. His commitment to this cause is incredible: he is saving 
lives and providing hope for millions more.

                          ____________________